Odette Cancer Centre

Running trials

• Recruiting

  LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma

  NCT06623461· Phase 2· Source

• Recruiting

  Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer

  NCT06641791· Phase 3· Source

• Recruiting

  Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

  NCT06439225· Phase 3· Source

• Recruiting

  Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

  NCT05640999· Phase 2· Source

• Recruiting

  Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

  NCT04918186· Phase 2· Source

• Active, not recruiting

  177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

  NCT04663997· Phase 2· Source

• Recruiting

  Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.

  NCT03061435· Source

• Active, not recruiting

  Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer

  NCT04619069· Phase 1/2· Source

• Active, not recruiting

  Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer

  NCT03784755· Source

• Active, not recruiting

  De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma

  NCT03822897· Phase 2· Source

• Active, not recruiting

  CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

  NCT03624543· Phase 2· Source

• Active, not recruiting

  Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT02905318· Phase 2· Source

• Active, not recruiting

  Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer

  NCT02960087· Source

• Recruiting

  Duration of Anti-PD-1 Therapy in Metastatic Melanoma

  NCT02821013· Phase 3· Source

• Recruiting

  Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer

  NCT04838899· Source

• Active, not recruiting

  Prostate Advances in Comparative Evidence

  NCT01584258· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Melanoma2 recruiting
• Prostate cancer2 recruiting
• Cervical cancer1 recruiting
• Endometrial cancer1 recruiting
• Head and neck cancer1 recruiting
• Ovarian cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure

  NCT04442048· Phase 3· Source

• Completed

  Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

  NCT02788773· Phase 2· Source

• Completed

  Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

  NCT02273375· Phase 3· Source

• Completed

  Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

  NCT00819208· Source